Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s flagship journal Circulation.

Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm

Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease,

February 8, 2024

Evaluating a machine learning tool for predicting hospital-acquired acute kidney injury

Hospital-acquired acute kidney injury (HA-AKI) is a common complication in hospitalized patients that can lead to chronic kidney disease and is associated with longer hospital

February 17, 2024

European Parliament adopts pharma legislative revamp by wide margin

Members of the European Parliament on Wednesday voted overwhelmingly in favor of the first pharma-related legislative overhaul in about two decades. If ultimately agreed to

April 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.